EUVIMEDEUVIMED entdecken
Crossref

Mechanism of low molecular weight impurity formation in an IgG1 monoclonal antibody formulation

Pinaki Basu, Nidhi Verma, Sigireddi Indra Kumar, Maya Nanath, Sireesha Goswamy Kaligatla, Giridhar Sivalanka, Veerabhadra Madurai Veeraraghavan, Lovisha Aggarwal, Sunil A Nankar, Ravi Kumar Marikanti, Murali Jayaraman

Journal of Pharmaceutical Sciences · 2025

DOI: 10.1016/j.xphs.2024.12.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Sciences, 2025. Verfasst von Pinaki Basu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Formulation and Drug Product Development, Biologics, Dr. Reddy's Laboratories, Hyderabad, India. Hauptthemen laut MEDLINE: Immunoglobulin G, Antibodies, Monoclonal, Drug Contamination, Biosimilar Pharmaceuticals. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Formulation robustness study was performed for a biosimilar monoclonal antibody (IgG1) manufactured at Dr. Reddy's Laboratory, where the pH and concentration level of excipients in the drug product formulation were systematically varied from the target formulation. It was observed that the IgG1 formulation having relatively low pH and high citrate (buffer salt) concentration were predisposed to the formation of low molecular weight impurities. Mass spectrometry analysis of the mAb1 fragments detected the pyroglutamate species from LC-LC dimer and fragmentation in the -DKTH- amino acid sequence of the heavy chain. Blind docking indicated binding of citrate with Lysine 222 residue in the proximity of Cys224 could have potentially fragmented IgG1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin GAntibodies, MonoclonalDrug ContaminationBiosimilar PharmaceuticalsMolecular WeightHydrogen-Ion ConcentrationExcipientsMolecular Docking SimulationChemistry, PharmaceuticalMass Spectrometry

Stichwörter der Autor:innen

Degradation product(s)FormulationMass spectrometry (MS)Monoclonal antibody(s)Protein formulation(s)

Substanzen

Immunoglobulin GAntibodies, MonoclonalExcipientsBiosimilar Pharmaceuticals

Autor:innen und Institutionen

  • Formulation and Drug Product Development, Biologics, Dr. Reddy's Laboratories, Hyderabad, India.
  • Data Analytics, Biologics, Dr. Reddy's Laboratories, Hyderabad, India.
  • Formulation and Drug Product Development, Biologics, Dr. Reddy's Laboratories, Hyderabad, India. Electronic address: muralijayaraman@drreddys.com.

Zitieren

APA

Basu, P., Verma, N., Indra Kumar, S., Nanath, M., Kaligatla, S. G., Sivalanka, G., Veeraraghavan, V. M., Aggarwal, L., A Nankar, S., Marikanti, R. K., & Jayaraman, M. (2025). Mechanism of low molecular weight impurity formation in an IgG1 monoclonal antibody formulation. Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.xphs.2024.12.024

Vancouver

Basu P, Verma N, Indra Kumar S, Nanath M, Kaligatla SG, Sivalanka G, et al. Mechanism of low molecular weight impurity formation in an IgG1 monoclonal antibody formulation. Journal of Pharmaceutical Sciences. 2025. doi:10.1016/j.xphs.2024.12.024

BibTeX
@article{Basu2025,
  author = {Basu, Pinaki and Verma, Nidhi and Indra Kumar, Sigireddi and Nanath, Maya and Kaligatla, Sireesha Goswamy and Sivalanka, Giridhar and Veeraraghavan, Veerabhadra Madurai and Aggarwal, Lovisha and A Nankar, Sunil and Marikanti, Ravi Kumar and Jayaraman, Murali},
  title = {Mechanism of low molecular weight impurity formation in an IgG1 monoclonal antibody formulation},
  journal = {Journal of Pharmaceutical Sciences},
  year = {2025},
  doi = {10.1016/j.xphs.2024.12.024}
}
Kostenlos starten →